clinical trial · NCT01490086
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
Acute SchizophreniaSchizoaffective DisorderRP5063placeboaripiprazole
brief summary
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
started
Dec 1, 2011
primary completion
Mar 1, 2013
completion
Mar 1, 2013
last updated
Aug 8, 2025
official title
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol